SCYNEXIS, Inc. (SCYX): Price and Financial Metrics
GET POWR RATINGS... FREE!
SCYX POWR Grades
- Growth is the dimension where SCYX ranks best; there it ranks ahead of 85.81% of US stocks.
- The strongest trend for SCYX is in Growth, which has been heading up over the past 177 days.
- SCYX ranks lowest in Quality; there it ranks in the 0th percentile.
SCYX Stock Summary
- SCYX's price/sales ratio is 14.67; that's higher than the P/S ratio of 92.99% of US stocks.
- Revenue growth over the past 12 months for SCYNEXIS INC comes in at -66.86%, a number that bests merely 2.91% of the US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SCYX comes in at -135.54% -- higher than that of only 4.43% of stocks in our set.
- Stocks that are quantitatively similar to SCYX, based on their financial statements, market capitalization, and price volatility, are NURO, BKYI, WPRT, CTSO, and KMDA.
- SCYX's SEC filings can be seen here. And to visit SCYNEXIS INC's official web site, go to www.scynexis.com.
SCYX Valuation Summary
- In comparison to the median Healthcare stock, SCYX's price/sales ratio is 673.68% higher, now standing at 14.7.
- Over the past 108 months, SCYX's price/sales ratio has gone up 10.2.
Below are key valuation metrics over time for SCYX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SCYX | 2023-03-24 | 14.7 | 3.6 | -0.8 | -0.5 |
| SCYX | 2023-03-23 | 14.1 | 3.4 | -0.8 | -0.5 |
| SCYX | 2023-03-22 | 15.7 | 3.8 | -0.8 | -0.6 |
| SCYX | 2023-03-21 | 12.2 | 3.0 | -0.7 | -0.4 |
| SCYX | 2023-03-20 | 9.0 | 2.2 | -0.5 | -0.2 |
| SCYX | 2023-03-17 | 9.0 | 2.2 | -0.5 | -0.2 |
SCYX Growth Metrics
- Its 4 year net income to common stockholders growth rate is now at -36.6%.
- Its year over year cash and equivalents growth rate is now at 3.41%.
- Its 4 year net cashflow from operations growth rate is now at -68.14%.
The table below shows SCYX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 4.164 | -82.597 | -77.623 |
| 2022-06-30 | 3.123 | -76.675 | -48.644 |
| 2022-03-31 | 1.8 | -69.789 | -33.641 |
| 2021-12-31 | 13.163 | -54.56 | -32.866 |
| 2021-09-30 | 12.566 | -45.612 | -46.334 |
| 2021-06-30 | 12.05 | -38.895 | -44.82 |
SCYX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SCYX has a Quality Grade of C, ranking ahead of 29.3% of graded US stocks.
- SCYX's asset turnover comes in at 0.134 -- ranking 232nd of 682 Pharmaceutical Products stocks.
- ACER, QURE, and MNOV are the stocks whose asset turnover ratios are most correlated with SCYX.
The table below shows SCYX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.134 | 1 | -3.908 |
| 2021-03-31 | 0.169 | 1 | -5.208 |
| 2020-12-31 | 0.000 | NA | -3.192 |
| 2020-09-30 | 0.000 | NA | -1.322 |
| 2020-06-30 | 0.000 | NA | -1.486 |
| 2020-03-31 | 0.001 | 1 | -1.353 |
SCYX Price Target
For more insight on analysts targets of SCYX, see our SCYX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $24.36 | Average Broker Recommendation | 1.36 (Strong Buy) |
SCYX Stock Price Chart Interactive Chart >
SCYX Price/Volume Stats
| Current price | $1.67 | 52-week high | $4.40 |
| Prev. close | $1.82 | 52-week low | $1.15 |
| Day low | $1.60 | Volume | 212,600 |
| Day high | $1.85 | Avg. volume | 419,068 |
| 50-day MA | $1.60 | Dividend yield | N/A |
| 200-day MA | $2.09 | Market Cap | 54.54M |
SCYNEXIS, Inc. (SCYX) Company Bio
SCYNEXIS, Inc., a pharmaceutical company, develops and commercializes novel anti-infectives to address unmet therapeutic needs. Its lead product candidate includes SCY-078, which is in Phase I clinical trials of the intravenous formulation; Phase II clinical trials for the treatment of invasive candida infections; and Phase II clinical trials for unmet medical needs, such as vulvovaginal candidiasis. The company was founded in 1999 and is based in Jersey City, New Jersey.
Latest SCYX News From Around the Web
Below are the latest news stories about SCYNEXIS INC that investors may wish to consider to help them evaluate SCYX as an investment opportunity.
CDC Rings Alarm About Deadly Fungus. 6 Things to Know.The number of infections from the Candida Auris fungus, which can be deadly for people who are already sick, is small but rapidly growing. |
SCYNEXIS, Inc. (NASDAQ:SCYX) insiders are still down US$113k after purchasing last year, recent gain helped regain some lossesSome of the losses seen by insiders who purchased US$236k worth of SCYNEXIS, Inc. ( NASDAQ:SCYX ) shares over the past... |
Analyst Sees Multiple Chances With Over 300% Upside Potential For This Fungal Infections StockGuggenheim has initiated coverage on SCYNEXIS Inc (NASDAQ: SCYX) with a Buy rating and a price target of $8. The anti-infectives space remains out of favor with investors, but SCYNEXIS offers a unique opportunity given that ibrexafungerp is already approved to treat vulvovaginal candidiasis (VVC), and has shown promising early data against more severe invasive infections, writes the analyst. In October, SCYNEXIS announced a new strategic direction to refocus its resources on the clinical develop |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with an overview of the biggest pre-market stock movers traders need to know about for Monday! |
SCYNEXIS (NASDAQ:SCYX) shareholders are up 14% this past week, but still in the red over the last five yearsIt's nice to see the SCYNEXIS, Inc. ( NASDAQ:SCYX ) share price up 14% in a week. But that doesn't change the fact that... |
SCYX Price Returns
| 1-mo | 12.08% |
| 3-mo | 7.05% |
| 6-mo | -30.42% |
| 1-year | -58.46% |
| 3-year | -77.31% |
| 5-year | -87.54% |
| YTD | 7.05% |
| 2022 | -74.43% |
| 2021 | -20.26% |
| 2020 | -15.93% |
| 2019 | 89.58% |
| 2018 | -79.31% |
Continue Researching SCYX
Want to do more research on Scynexis Inc's stock and its price? Try the links below:Scynexis Inc (SCYX) Stock Price | Nasdaq
Scynexis Inc (SCYX) Stock Quote, History and News - Yahoo Finance
Scynexis Inc (SCYX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...